KIT and gastrointestinal stromal tumor: Imatinib is an approved inhibitor of BCR-ABL, and KIT tyrosine kinase is used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and KIT-positive gastrointestinal stromal tumors (GIST), respectively [43,96].